

ePQS and eCTD – Inspection Services

Kim Richards

Technical Officer (Inspector)

Inspection services, Prequalification Unit

Regulation and Prequalification Department

Access to Medicines and Health Products Division

WORLD HEALTH ORGANIZATION

What is ePQS?

ePQS is a platform for the processing of prequalification information for -

- Medicines,
- Diagnostics,
- Vector control products,
- Vaccines,
- Immunization devices,
- Quality control laboratories and
- Inspections.

ePQS consists of several integrated packages

ePQS consists of several integrated software packages.

- A central Salesforce-based database
- An externally facing Salesforce-based community portal
- An integrated Document Management System
- And a related eCTD repository

The external Salesforce-based community portal has been designed to allow users to –

- View records related to their application/site/product,
- Submit applications,
- Upload and download documents in a secure environment,
- View and monitor notifications for pending activities.

<https://extranet.who.int/prequal/>



**Prequalification of
Medical Products**
IVDs, Medicines, Vaccines and Immunization
Devices, Vector Control

[Contact us](#) | [Glossary and Acronyms](#) | [FAQ](#) | [Complaints](#) | [Feedback](#)



[Product Streams](#) ▾

[Events](#)

[News](#)

[ePQS](#)

[About](#)



WHO PREQUALIFICATION





[Product Streams](#) ▾

[Events](#)


[News](#)

[ePQS](#)

[About](#)



ePQS Portal



The **ePQS Portal** is the externally-facing Salesforce Community site of the WHO Prequalification Unit's new ePQS system. ePQS is a platform for the processing of Prequalification Information for medicines, diagnostics, vector control products, vaccines, immunization devices, quality control laboratories and inspections.

Within the portal, users will have the ability to:

General user information can be found here -

<https://extranet.who.int/prequal/epqs-portal>

Within the portal, users will have the ability to:

- View Salesforce records relevant to the user
- Submit applications
- Upload and download documents securely
- View and monitor notifications for pending activities

Registration to open early
2024



Registered users will be able to access the Portal at this link: <https://who.my.site.com/ePQS/s/login/>

Guidance notes related to the features of the portal, processes around applications, document submissions, and many other topics will be progressively posted to this webpage.

Webinars will be announced soon and regular clinics will be held post-go live to support users, answer questions, and identify issues in order to make continuous improvements.

NOTE: The portal will be opened from January 2024 and commence with user registrations thereon.

General Portal Information

- [ePQS - Accounts Contacts Users and Record Visibility](#)
- [ePQS - Creating or editing a Contact or Account](#)
- [ePQS - Portal Introduction and Features](#)
- [ePQS - Terms and Conditions of use \(4 October 2023\)](#)
- [ePQS - User Registration and accessing the ePQS Portal](#)



What will be visible -

- Accounts/records to which you are directly related to,
- Contacts,
- Product records – related to accounts that are listed under the applicants organisation,
- Activity records assigned,
- Completed inspection records.

[Home](#)
[Organizations](#)
[Contacts](#)
[Activities](#)
[Cases](#)
[ePQS Products](#)
[Inspections](#)
[NRA CRP Agreements](#)
[Application Wizard](#)

[Submit an application](#)

[Create Account or Contact](#)

[Edit an Account or Contact](#)

[Change a Record Contact](#)

COMMONLY USED LISTS

- [Medicine Storage Conditions](#)
- [WHO Vaccine Names](#)
- [Medicines Pharmaceutical Ingredients](#)
- [VC Active Ingredients/Synergist Name](#)
- [QCLm Generic Name \(INN\)](#)
- [Post-Prequalification Changes](#)

[View ePQS Registered Accounts](#)

FEATURED

FAQs	Prequalification Information	EPQS Training Material
----------------------	--	--

ePQS

Search...

Search



[Home](#)
[Organizations](#)
[Contacts](#)
[Activities](#)
[Cases](#)
[ePQS Products](#)
[Inspections](#)
[NRA CRP Agreements](#)
[Application Wizard](#)

Inspection
I-00056

+ Follow

Printable View

Conga Inspection

Site	Inspection Status	Inspection Type	Final Inspection Outcome
PQT Pharmaceuticals (Site II) - Test	Completed	Routine inspection	Compliant (On-site Inspection)

[Details](#)
[Related](#)
[Preview Documents](#)
[Document Download](#)
[Document Submission](#)

Comments

APIMF394 , HA742 , WHOAPI-219 , HA516 , HA561 , HA562 , HA498 , HA538 , HA448 , HA549 , APIMF173 , APIMF219 , APIMF258 , WHOAPI-258 , HA611 Routine inspection

Information

ePQS Inspection ID
INSP-API-2015-0291

Inspection Status
Completed

Is Inspection a Priority

Inspection Type
Routine inspection

Initial Inspection Request

Trigger Reason

Joint Inspection

Site Detail

Site
[PQT Pharmaceuticals \(Site II\) - Test](#)

Site (Legal)
PQT Pharmaceuticals - Test

Site Address

Previous Inspection Type
Routine inspection

Previous Inspection Record Number
[I-00054](#)

Previous Final Inspection Outcome
Compliant (On-site Inspection)

Revised Inspection Due Date

Reason for Revising Inspection Due Date

Latitude
0.0000

Longitude
0.0000

Site Contact

▼ Desk Assessment

Desk Assessment – Basis for Outcome

Date of Last Inspection by NRA

Should Desk Assessment be placed on hold

Reason for hold

Desk Explanation for Hold

Hold Start Date

Hold End Date

▼ Onsite

Inspection Start Date – Proposed
22/07/2019

Inspection End Date – Proposed
24/07/2019

Should Onsite Inspect be placed on hold?

Onsite Inspection Reason for Hold

Onsite Inspection Hold Start Date

Onsite Inspection Hold End Date

Inspection Start Date – Agreed

Inspection End Date – Agreed

Start Date Change Justification

▼ Final Inspection Outcome

Date Inspection Completed①
26/05/2020

Internal Inspection Supporting Decision

External Inspection Supporting Decision

Date of Desk Assessment Completion

Desk Assessment Outcome

Desk Assessment Final Comments

Reference Authority

Inspection Start Date – Actual
22/07/2019

Inspection End Date – Actual
24/07/2019

Onsite Explanation for Hold

Onsite Inspection Outcome
Compliant (On-site Inspection)

Date Onsite Inspection closed
26/05/2020

Onsite Inspection Comments

Target Re-inspection Date①

ePQS

Search...

Search



apqpa

[Home](#)
[Organizations](#)
[Contacts](#)
[Activities](#)
[Cases](#)
[ePQS Products](#)
[Inspections](#)
[NRA CRP Agreements](#)
[Application Wizard](#)



ePQS Product
FPP Test Product

+ Follow

Printable View

Publish

Clone



Product Type
Finished Pharmaceutical Product

Applicant Organization
[ePQS Test Account 2 - NonStateActor](#)

Date of Prequalification/Acceptance

[Details](#)
[Related](#)
[Preview Document](#)
[Document Download](#)

▼ Information

WHO Product ID
FPP Test Product

Product Type
Finished Pharmaceutical Product

Product Status
Prequalified

Responsible team
Medicines Team

Applicant Organization
[ePQS Test Account 2 - NonStateActor](#)

Applicant Organization (Legal)
[ePQS Test Account 2 - NonStateActor](#)

Primary Contact
[ePQS External Applicant 3](#)

Secondary Contact

Alternative Secondary Contact

▼ Original Application Dates

Date Application Accepted for Assessment
[09/01/2013](#)

▼ Product Dates

Date of Prequalification/Acceptance

[Home](#)
[Organizations](#)
[Contacts](#)
[Activities](#)
[Cases](#)
[ePQS Products](#)
[Inspections](#)
[NRA CRP Agreements](#)
[Application Wizard](#)

Contact

ePQS External Expert 1

Job Title

Account Name

Phone (2) ▼

Email

Contact Owner

[ePQS Test Account 3](#)

[epqsuatenvironmentsanitytest@gmail.com](#)

[User16184741731295586380](#)

[Details](#)
[Related](#)
[Preview Documents](#)
[Download Documents](#)
[Preview Mx Documents](#)
[Download Mx Documents](#)

▼

Contact Information

Name

ePQS External Expert 1

Job Title

Status ⓘ

Email

[epqsuatenvironmentsanitytest@gmail.com](#)

Phone

Mobile

Fax

Gender ⓘ

▼

Organization

Account Name ⓘ

[ePQS Test Account 3](#)

▼

Identity

Language ⓘ

▼

Address Information

eCTD and PQ (Medicines and Vaccines)

- **Electronic Common Technical Document**
 - Used for the submitting regulatory information to the health authorities,
 - It provides a harmonized electronic means to submit documents,
 - Purpose to reduce the burden,
 - The Module 1 requirements have been posted on the WHO webpage,
 - The first webinar has occurred, and further webinars and industry clinics are planned as eCTD is implemented.

eCTD Transition phases

- Phase 1 (2024): optional eCTD submissions.
- Phase 2 (+1 year): Mandatory for new product applications.
- Phase 3 (+2 years): Mandatory all applications in eCTD.

- Home
- Product Streams ▾
 - Immunization Devices ▾
 - In Vitro Diagnostics ▾
 - Medicines ▾
 - Vaccines ▴
 - Vector Control Products ▾
 - Inspection Services ▾
- Events
- News ▾
- ePQS ▾
 - Guidance Documents
 - Prequalification Reports
 - Emergency Use Listing Procedure
 - Market Information
 - Risk Assessment - Snake Antivenom
 - eCTD ▾
- About

The transition timeline to eCTD

We are currently in Phase 0.

Phase	APIMF/API-PQ Products FPP Products FVP Products
Phase 0	Companies should take time to familiarize themselves with WHO PQT requirements and prepare legacy dossiers or new product dossiers in this format.
Phase 1	Companies may voluntarily submit applications for new products in eCTD format. Companies may voluntarily submit Post-PQ Change applications to convert existing prequalified Product dossiers to eCTD format.

General user information can be found here -

<https://extranet.who.int/prequal/ectd-portal>



[Product Streams](#) ▾

[Events](#)

[News](#)

[ePQS](#)

[About](#)

eCTD Portal

The Medicines and Vaccine assessment teams within the Prequalification Unit (PQT) are introducing an **eCTD facility** as part of the opening of the [ePQS Portal](#)

eCTD (electronic Common Technical Document) is a standard format for submitting Regulatory information (such as applications) to the Health Authorities, or in this case the Prequalification Unit. It provides a harmonized electronic means to submit in the Common Technical Document (CTD) of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) – www.ich.org

The purpose of introducing eCTD is to reduce the burden of document lifecycle management upon applicants and PQT, as well facilitating document review by assessors.

Submission of eCTD-based applications will occur via the ePQS portal.

Various reference documents to support companies to create an acceptable eCTD dossier are provided in the links below

Information pertaining to the practical steps aspects of submission are provided on the ePQS webpage

The transition timeline to eCTD

We are currently in Phase 0.

Phase	APIMF/API-PQ Products FPP Products FVP Products
Phase 0	Companies should take time to familiarize themselves with WHO PQT requirements and prepare legacy dossiers or new product dossiers in this format.
Phase 1	Companies may voluntarily submit applications for new products in eCTD format. Companies may voluntarily submit Post PQ Change applications to convert existing prequalified Product dossiers to

Validation of eCTD submissions

Prior to the eCTD submission itself, WHO recommends the use of a validator to ensure that the content fully complies with regulatory requirements and is valid. The validator used should be up to date at all times; detailed validation reports also facilitate the creation of a correct submission.

One example of such a tool is EXTEDO's EURSvalidator. You can find more information here: <https://www.extedo.com/software/submission-validation/eursvalidator>

Links

Webinars

[Implementing M1 for eCTD submissions submitted to the WHO Prequalification Unit \(PQT\). | EXTEDO \(Register here\)](#)

This webinar will be recorded and posted.

Documents

[eCTD - 2023 10 18 PQT Validation Criteria v 1.0](#)

[eCTD - FAQ WHO PQT](#)

[eCTD - WHO eCTD guidance for Industry](#)

[eCTD - WHO PQT eCTD checksums](#)

[eCTD - WHO PQT Technical Files](#)

[eCTD - WHO PQT Valid Values XML](#)

[eCTD - WHOPQT eCTD M1 Specification \(Files-Elements-Folders\)](#)

About Us

[History & Mission](#)

[What We Do](#)

[Funding](#)

Site Map

[Events](#)

[News](#)

[Faq](#)

WHO Links

[World Health Organization \(WHO\)](#)

[WHO Essential Medicines and Health Products](#)

[WHO Global Malaria Programme](#)

Thank you



WHO

20, Avenue Appia
1211 Geneva

Switzerland

www.who.int